Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.

Wilke C, Pujol-Calderón F, Barro C, Stransky E, Blennow K, Michalak Z, Deuschle C, Jeromin A, Zetterberg H, Schüle R, Höglund K, Kuhle J, Synofzik M.

Clin Chem Lab Med. 2019 May 9. pii: /j/cclm.ahead-of-print/cclm-2019-0015/cclm-2019-0015.xml. doi: 10.1515/cclm-2019-0015. [Epub ahead of print]

PMID:
31251725
2.

Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile.

Lerche S, Machetanz G, Wurster I, Roeben B, Zimmermann M, Pilotto A, Preische O, Stransky E, Deuschle C, Hauser AK, Schulte C, Lachmann I, Waniek K, Gasser T, Berg D, Maetzler W, Brockmann K.

Mov Disord. 2019 Jun 12. doi: 10.1002/mds.27731. [Epub ahead of print]

PMID:
31189032
3.

Parkinson's disease: evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study.

Lerche S, Wurster I, Röben B, Machetanz G, Zimmermann M, Bernhard F, Stransky E, Deuschle C, Schulte C, Hansson O, Zetterberg H, Gasser T, Berg D, Maetzler W, Brockmann K.

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):165-170. doi: 10.1136/jnnp-2018-318956. Epub 2018 Sep 25.

PMID:
30254084
4.

Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring.

Stoessel D, Stellmann JP, Willing A, Behrens B, Rosenkranz SC, Hodecker SC, Stürner KH, Reinhardt S, Fleischer S, Deuschle C, Maetzler W, Berg D, Heesen C, Walther D, Schauer N, Friese MA, Pless O.

Front Hum Neurosci. 2018 Jun 4;12:226. doi: 10.3389/fnhum.2018.00226. eCollection 2018.

5.

Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease.

Stoessel D, Schulte C, Teixeira Dos Santos MC, Scheller D, Rebollo-Mesa I, Deuschle C, Walther D, Schauer N, Berg D, Nogueira da Costa A, Maetzler W.

Front Aging Neurosci. 2018 Mar 5;10:51. doi: 10.3389/fnagi.2018.00051. eCollection 2018.

6.

Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles.

Lerche S, Schulte C, Srulijes K, Pilotto A, Rattay TW, Hauser AK, Stransky E, Deuschle C, Csoti I, Lachmann I, Zetterberg H, Liepelt-Scarfone I, Gasser T, Maetzler W, Berg D, Brockmann K.

Mov Disord. 2017 Dec;32(12):1780-1783. doi: 10.1002/mds.27199. Epub 2017 Nov 2.

PMID:
29094781
7.

Dementia with Lewy bodies: cerebrospinal fluid suppresses neuronal network activity.

Theiss S, Maetzler W, Deuschle C, Lerche H, Koch H, Dihné M.

Neuroreport. 2017 Nov 8;28(16):1061-1065. doi: 10.1097/WNR.0000000000000890.

PMID:
28953602
8.

Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia.

Wilke C, Gillardon F, Deuschle C, Hobert MA, Jansen IE, Metzger FG, Heutink P, Gasser T, Maetzler W, Blauwendraat C, Synofzik M.

Neurodegener Dis. 2017;17(2-3):83-88. doi: 10.1159/000448896. Epub 2016 Oct 20.

PMID:
27760429
9.

Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum.

Wilke C, Preische O, Deuschle C, Roeben B, Apel A, Barro C, Maia L, Maetzler W, Kuhle J, Synofzik M.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1270-1272. doi: 10.1136/jnnp-2015-312972. Epub 2016 May 17. No abstract available.

PMID:
27188986
10.

Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease.

Wilke C, Gillardon F, Deuschle C, Dubois E, Hobert MA, Müller vom Hagen J, Krüger S, Biskup S, Blauwendraat C, Hruscha M, Kaeser SA, Heutink P, Maetzler W, Synofzik M.

Curr Alzheimer Res. 2016;13(6):654-62.

PMID:
26971930
11.

Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors.

Bernhard FP, Heinzel S, Binder G, Weber K, Apel A, Roeben B, Deuschle C, Maechtel M, Heger T, Nussbaum S, Gasser T, Maetzler W, Berg D.

PLoS One. 2016 Mar 11;11(3):e0150552. doi: 10.1371/journal.pone.0150552. eCollection 2016.

12.

GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia.

Maetzler W, Deleersnijder W, Hanssens V, Bernard A, Brockmann K, Marquetand J, Wurster I, Rattay TW, Roncoroni L, Schaeffer E, Lerche S, Apel A, Deuschle C, Berg D.

PLoS One. 2016 Mar 3;11(3):e0149349. doi: 10.1371/journal.pone.0149349. eCollection 2016.

13.

Validating Alzheimer's disease micro RNAs using next-generation sequencing.

Keller A, Backes C, Haas J, Leidinger P, Maetzler W, Deuschle C, Berg D, Ruschil C, Galata V, Ruprecht K, Stähler C, Würstle M, Sickert D, Gogol M, Meder B, Meese E.

Alzheimers Dement. 2016 May;12(5):565-76. doi: 10.1016/j.jalz.2015.12.012. Epub 2016 Jan 22.

PMID:
26806387
14.

Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.

Brockmann K, Schulte C, Deuschle C, Hauser AK, Heger T, Gasser T, Maetzler W, Berg D.

Parkinsonism Relat Disord. 2015 Dec;21(12):1427-34. doi: 10.1016/j.parkreldis.2015.10.008. Epub 2015 Oct 14.

PMID:
26475624
15.

Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.

Heinzel S, Gold M, Deuschle C, Bernhard F, Maetzler W, Berg D, Dodel R.

PLoS One. 2014 Dec 3;9(12):e114566. doi: 10.1371/journal.pone.0114566. eCollection 2014.

16.

Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis.

Wilke C, Deuschle C, Rattay TW, Maetzler W, Synofzik M.

Neurobiol Aging. 2015 Feb;36(2):1072-4. doi: 10.1016/j.neurobiolaging.2014.10.019. Epub 2014 Oct 18.

PMID:
25453560
17.

In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 α-synuclein antibody.

Maetzler W, Pilotto A, Apel A, Deuschle C, Kuebart G, Heinzel S, Liepelt-Scarfone I, Schulte C, Reusch D, Schleicher E, Rothfuss O, Schneider A, Dodel R, Gasser T, Berg D.

Acta Neuropathol. 2014 Dec;128(6):893-5. doi: 10.1007/s00401-014-1364-1. Epub 2014 Nov 7. No abstract available.

PMID:
25376537
18.

Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls.

Maetzler W, Apel A, Langkamp M, Deuschle C, Dilger SS, Stirnkorb JG, Schulte C, Schleicher E, Gasser T, Berg D.

PLoS One. 2014 Feb 21;9(2):e88604. doi: 10.1371/journal.pone.0088604. eCollection 2014.

19.

Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study.

Mielke MM, Maetzler W, Haughey NJ, Bandaru VV, Savica R, Deuschle C, Gasser T, Hauser AK, Gräber-Sultan S, Schleicher E, Berg D, Liepelt-Scarfone I.

PLoS One. 2013 Sep 18;8(9):e73094. doi: 10.1371/journal.pone.0073094. eCollection 2013.

20.

Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia.

Maetzler W, Tian Y, Baur SM, Gauger T, Odoj B, Schmid B, Schulte C, Deuschle C, Heck S, Apel A, Melms A, Gasser T, Berg D.

PLoS One. 2012;7(10):e48042. doi: 10.1371/journal.pone.0048042. Epub 2012 Oct 25.

21.

Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease.

Schmid SP, Schleicher ED, Cegan A, Deuschle C, Baur S, Hauser AK, Synofzik M, Srulijes K, Brockmann K, Berg D, Maetzler W.

Mov Disord. 2012 Feb;27(2):288-92. doi: 10.1002/mds.23984. Epub 2011 Oct 21.

PMID:
22021190

Supplemental Content

Loading ...
Support Center